Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Shibata

Showing results (821-830 of 840) with videos related to

Pageof 84
Sort By:
Gynecologic Oncology|June 1, 2000
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-upR J Morgan, P Braly, L Leong, et al.
British Journal of Cancer|August 15, 2002
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancerG Somlo, J F Simpson, P Frankel, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapyR J Morgan, T Synold, B I Carr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignanciesM L Tetef, T W Synold, W Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survivalG Somlo, J H Doroshow, S J Forman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034H L McLeod, J Cassidy, R H Powrie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 7, 2012
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancerA VanderWalde, W Ye, P Frankel, et al.
Bone Marrow Transplantation|January 10, 2002
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancerR J Morgan, J H Doroshow, L Leong, et al.
Blood|March 1, 1997
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancerG Somlo, I Sniecinski, T Odom-Maryon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 13, 2001
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignanciesG Somlo, W Chow, V Hamasaki, et al.
Pageof 84

Showing results (821-830 of 840) with videos related to

Sort By:
Pageof 84
Gynecologic Oncology|June 1, 2000
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-upR J Morgan, P Braly, L Leong, et al.
British Journal of Cancer|August 15, 2002
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancerG Somlo, J F Simpson, P Frankel, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapyR J Morgan, T Synold, B I Carr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignanciesM L Tetef, T W Synold, W Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survivalG Somlo, J H Doroshow, S J Forman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034H L McLeod, J Cassidy, R H Powrie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 7, 2012
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancerA VanderWalde, W Ye, P Frankel, et al.
Bone Marrow Transplantation|January 10, 2002
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancerR J Morgan, J H Doroshow, L Leong, et al.
Blood|March 1, 1997
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancerG Somlo, I Sniecinski, T Odom-Maryon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 13, 2001
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignanciesG Somlo, W Chow, V Hamasaki, et al.
Pageof 84